Controversies in Intrapatient Melanoma BRAFV600E Mutation Status

被引：5
|
作者：
Riveiro-Falkenbach, Erica [1 ]
Santos-Briz, Angel [2 ]
Rios-Martin, Juan J. [3 ]
Rodriguez-Peralto, Jose L. [1 ]
机构：
[1] Univ Complutense, Sch Med, Inst I 12, Dept Pathol, Madrid, Spain
[2] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Dept Pathol, Salamanca, Spain
[3] Hosp Univ Virgen Macarena, Dept Pathol, Seville, Spain
来源：
AMERICAN JOURNAL OF DERMATOPATHOLOGY | 2017年 / 39卷 / 04期
关键词：
melanoma; BRAF(V600E); intrapatient status; BRAF MUTATIONS; METASTATIC MELANOMA; CLINICAL-IMPLICATIONS; TARGETED THERAPY; IMMUNOHISTOCHEMISTRY; VEMURAFENIB; V600E; HETEROGENEITY; LESIONS; KRAS;
D O I：
10.1097/DAD.0000000000000710
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Therapies targeting the BRAF(V600) oncogene have improved the overall and disease-free survival of patients with advanced melanomas. An unresolved issue in clinical practice is the existence (or not) of BRAF(V600)-mutated and BRAF(V600)-nonmutated tumors in individual patients (intrapatient BRAF mutation heterogeneity), which may serve as a mechanism of resistance to BRAF inhibitors or lead to diagnostic problems. Different research groups have reported differing results after analyzing the BRAF mutation statuses of multiple melanoma tumors. Herein, we present a brief revision of the literature on this controversial topic and propose a theory to justify the divergence of the results found in the literature.
引用
下载
收藏
页码：291 / 295
页数：5
相关论文
共 50 条
  • [11] BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
    Wilmott, J. S.
    Menzies, A. M.
    Haydu, L. E.
    Capper, D.
    Preusser, M.
    Zhang, Y. E.
    Thompson, J. F.
    Kefford, R. F.
    von Deimling, A.
    Scolyer, R. A.
    Long, G. V.
    BRITISH JOURNAL OF CANCER, 2013, 108 (04) : 924 - 931
  • [12] Melanoma Drug Approved for Patients With BRAFV600E
    Smart, Michael
    ONCOLOGY NURSING FORUM, 2011, 38 (06) : 739 - 740
  • [13] Absence of BRAFV600E mutation in odontogenic keratocysts
    Franca, Josiane Alves
    de Sousa, Silvia Ferreira
    Diniz, Marina Goncalves
    Fontes Pereira, Thais dos Santos
    Campos de Resende, Taynara Asevedo
    dos Santos, Jean Nunes
    Gomez, Ricardo Santiago
    Gomes, Carolina Cavalieri
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2018, 47 (02) : 186 - 191
  • [14] Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA
    Burjanivova, Tatiana
    Malicherova, Bibiana
    Grendar, Marian
    Minarikova, Eva
    Dusenka, Robert
    Vanova, Barbora
    Bobrovska, Martina
    Pecova, Tatiana
    Homola, Igor
    Lasabova, Zora
    Plank, Lukas
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2019, 23 (04) : 241 - 245
  • [15] BRAFV600E mutation in the diagnosis of unicystic ameloblastoma
    Pereira, Nubia Braga
    Alves Pereira, Karuza Maria
    Coura, Bruna Pizziolo
    Diniz, Marina Goncalves
    de Castro, Wagner Henriques
    Gomes, Carolina Cavalieri
    Gomez, Ricardo Santiago
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2016, 45 (10) : 780 - 785
  • [16] Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
    Panka, David J.
    Buchbinder, Elizabeth
    Giobbie-Hurder, Anita
    Schalck, Aislyn P.
    Montaser-Kouhsari, Laleh
    Sepehr, Alireza
    Lawrence, Donald P.
    McDermott, David F.
    Cohen, Rachel
    Carlson, Alexander
    Wargo, Jennifer A.
    Merritt, Ryan
    Seery, Virginia J.
    Hodi, F. Stephen
    Gunturi, Anasuya
    Fredrick, Dennie
    Atkins, Michael B.
    Iafrate, A. John
    Flaherty, Keith T.
    Mier, James W.
    Sullivan, Ryan J.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 3210 - 3218
  • [17] Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients
    Salvianti, Francesca
    Massi, Daniela
    De Giorgi, Vincenzo
    Gori, Alessia
    Pazzagli, Mario
    Pinzani, Pamela
    CANCER BIOMARKERS, 2019, 26 (03) : 271 - 279
  • [18] The status of BRAFV600E mutation among Egyptian patients with papillary thyroid carcinoma
    El Tawil A.
    Mehaney D.
    Anis S.
    Salama A.
    Khattab H.
    El-Refaei S.
    Comparative Clinical Pathology, 2015, 24 (4) : 715 - 720
  • [19] FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
    Kim, Geoffrey
    Mckee, Amy E.
    Ning, Yang-Min
    Hazarika, Maitreyee
    Theoret, Marc
    Johnson, John R.
    Xu, Qiang Casey
    Tang, Shenghui
    Sridhara, Rajeshwari
    Jiang, Xiaoping
    He, Kun
    Roscoe, Donna
    McGuinn, W. David
    Helms, Whitney S.
    Russell, Anne Marie
    Miksinski, Sarah Pope
    Zirkelbach, Jeanne Fourie
    Earp, Justin
    Liu, Qi
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (19) : 4994 - 5000
  • [20] Immunohistochemical detection of BRAFV600E mutation in patients with metastatic melanoma and correlation with molecular methods
    Kostopoulou, A.
    Dimitriadi, A.
    Pappa, S.
    Kyrodimou, E.
    Theodosiou, D.
    Gogas, H.
    Tsoutsos, D.
    Choreftaki, T.
    Papaliodi, E.
    VIRCHOWS ARCHIV, 2014, 465 : S186 - S186
12345